Actimed completes enrollment in Phase 2a of S-pindolol with semaglutide
The two-part PROACT study tests muscle preservation both alongside semaglutide and in patients who have already stopped the drug.
PR
By Priya Raman · Science Reporter
Sep 24 02:48 ETSource: The Clinical Trial Vanguard
The wire
- 01Actimed Therapeutics finished recruiting its randomized, double-blind, placebo-controlled PROACT Phase 2a trial of S-pindolol benzoate (ACM 001.1) in obese adults during and after semaglutide therapy.
- 02Lean mass loss during GLP-1 treatment and muscle-related weight regain after discontinuation are unresolved clinical problems; PROACT is an early test of an adjunct aimed at both windows.
- 03ACM 001.1 combines nonselective beta-blockade with partial beta-2 agonism and was originally developed in cancer cachexia; this is a Phase 2a study and no efficacy data have been reported.
From the source
Read at clinicaltrialvanguard.comActimed Completes Enrollment in PROACT Trial of S-Pindolol With Semaglutide
Actimed Therapeutics has finished enrolling patients in its PROACT Phase 2a study, setting up a near-term readout on whether S-pindolol benzoate (ACM 001.1) can do something GLP-1 drugs do not: preserve muscle while fat comes off. That gap is the trial’s entire rationale. Semaglutide and other approved weight-management agents drive substantial weight loss, but a meaningful share of the weight los
